Crowdonomics
Valion Bio, Inc.

Reg A+ · Equity · Aug 2024

WithdrawnReg A+Equity
via Maxim Group LLC · last checked Aug 16, 2026
Raised
$0 / $20M max
0% of ceiling
Investors
—
—
Estimated pre-money
$54.6M
—

Financials disclosed in this offering

FY2023 · hover for source
$1.2M
−$8.2M
FY2023
RevenueNet income
Metric
FY2023 audited
Income statement
Revenue
$1,176,000
Cost of goods sold
$889,000
Gross margin
24%
Net income
-$8,244,000
Balance sheet
Cash
$3,395,000
Accounts receivable
$174,000
Total assets
$5,157,000
Long-term debt
$0
Total liabilities
$1,577,000
Other
Headcount
9

The fiscal years the issuer disclosed in this offering’s filing, as filed. Full history on the company page.

Amendments to this offering

3 amendments
  1. Dec 13, 2024
    Terms not yet extracted from this filing
    Form 1-A/A on EDGAR ↗
  2. Nov 7, 2024
    Terms not yet extracted from this filing
    Form 1-A/A on EDGAR ↗
  3. Oct 4, 2024
    Terms not yet extracted from this filing
    Form 1-A/A on EDGAR ↗

Each line compares the amendment with the previous filing of this offering. Form 1-A amendments state no reason; those filed before qualification are usually responses to SEC staff review.

Deal terms

Est. pre-money$54.6M
Price / share$3.00
Price / share today$51.00
Shares offered6,666,667

Estimated, not stated: $3.00 × 18,206,489 securities outstanding.

$3.00 as sold; $51.00 after the Mar 2025 split (1:17) (Form 10-K, p. 1).

Offering details

Target—
Max$20,000,001
Min investment—
OpenedAug 16, 2024
Deadline—
ClosedSep 17, 2025
Days active397

Links & provenance

Source: SEC EDGAR
0001683168-24-005833
Last synced Aug 16, 2026

About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.